MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced that its artificial intelligence-driven voice analytics technology is nearing final product testing ahead of its first commercial pilot, with intoxication detection accuracy reaching up to 83% under certain testing conditions. The company reported that its prediction models, tested with and without sober baseline tracking, have exceeded the accuracy of some commercially available cheek swab tests. MindBio plans additional human testing over the next two to three weeks before launching its first commercial pilot.
The company expects its initial commercially ready product to integrate proprietary Voice AI software with its previously announced Edge AI Intoxication Detection Kiosk, initially operating in Spanish. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
This development matters because workplace intoxication is a persistent safety and liability concern in high-risk industries such as mining, aviation, and construction, where traditional testing methods like cheek swabs can be invasive, time-consuming, and sometimes less accurate. A voice-based AI kiosk could offer a faster, non-invasive screening tool, potentially reducing accidents and improving compliance. If MindBio's technology performs as reported in real-world pilots, it could disrupt the estimated multi-billion-dollar drug and alcohol testing market and provide employers with a scalable alternative.
Separately, MindBio announced a nonbrokered private placement of up to 3,888,889 units at $0.09 per unit for gross proceeds of up to CA$350,000. Each unit will consist of one common share and one-half of a common share purchase warrant, with each whole warrant exercisable at $0.16 per share for 36 months following closing. Proceeds are intended to support general working capital, annual audit and legal expenses, and OTC and CSE listing costs. The financing, though modest, signals that the company is securing funds to advance its technology toward commercialization without relying on a broker, which may appeal to existing investors.
For readers and industry observers, the announcement highlights the growing intersection of AI and workplace safety. Companies in mining, aviation, construction and law enforcement may soon have access to a new tool for intoxication screening that could be integrated into daily operations. However, the technology still faces regulatory scrutiny and real-world validation. The upcoming commercial pilot will be a key test of whether the reported accuracy holds up outside controlled testing conditions. Investors can follow further updates via the company's newsroom at https://ibn.fm/MBQIF.
As the company moves closer to market, its progress will be watched by potential enterprise customers and competitors alike. The full press release is available at https://ibn.fm/ErHN1. This news was disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising, and was reported by TechMediaWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN. TechMediaWire reaches audiences through InvestorWire and provides corporate communications solutions to help companies gain visibility. Readers should review the full disclaimer for important information about this content.


